AstraZeneca (AZN.L): 2Q26 First Take: EPS beat aided by tax with underlying in-line; some-vedotin key update within pipeline

Research evidence excerpt

AstraZeneca (AZN.L): 2Q26 First Take: EPS beat aided by tax with underlying in-line; some-vedotin key update within pipeline

s information is being provided to you for information purposes only and is

not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of

securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under

applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities

and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman

Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. Hong Kong: Further information on the

securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information

on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research

Analyst - SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate

Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of

the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies

referred to in this research report. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or